What is it about?
Cinacalcet is an important drug to decrease the serum level of PTH in chronic kidney disease. However, this study has shown that the cinacalcet was not associated with decreases in all-cause mortality or CVD mortality in younger stage 5 CKD patients with high PTH levels (>600 pg/mL). Because clinical effect of cinacalcet-mediated lowering of PTH levels is highly variable according to patients' age, eGFR, biochemical level. Therefore, adding cinacalcet to the current standard care for younger stage 5 CKD patients should be re-evaluated.
Featured Image
Perspectives
This study has shown that diversity of the patient population in terms of the patients’ age, health insurance policies and the target serum level of biochemical and PTH, and GFR may cause variations in the response to cinacalcet treatment. Therefore, it is important that Cinacalcet therapy for CKD-MBD-related SHPT should be managed according to the above multivariable-factors to determine the true effect of cinacalcet.
Hye Yeon Sin
Duksung Women's University
Read the Original
This page is a summary of: Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital, Journal of Clinical Pharmacy and Therapeutics, June 2017, Wiley,
DOI: 10.1111/jcpt.12565.
You can read the full text:
Resources
Contributors
The following have contributed to this page
